Phase II Randomised Controlled Trial to Evaluate Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette-Guerin Vaccination in Infants of HIV Infected Mothers

Trial Profile

Phase II Randomised Controlled Trial to Evaluate Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette-Guerin Vaccination in Infants of HIV Infected Mothers

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs BCG vaccine (Primary) ; MVA 85A (Primary) ; Candida antigen
  • Indications Tuberculosis
  • Focus Adverse reactions; Biomarker
  • Acronyms MVA(TB)029
  • Most Recent Events

    • 26 Sep 2017 Results published in the Clinical Infectious Diseases
    • 10 Jun 2017 Biomarkers information updated
    • 30 Jan 2013 Planned initiation date is 1 Oct 2012 as identified on ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top